Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian C Gaertner

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|May 3, 2013
Whole body assessment by ¹⁸F-FDG PET in a patient with infective endocarditisAtsuro Masuda, Osamu Manabe, Masanao Naya, et al.
Oncotarget|December 29, 2016
Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade gliomaSied Kebir, Zain Khurshid, Florian C Gaertner, et al.
Oncotarget|September 15, 2017
Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancerFlorian C Gaertner, Khalil Halabi, Hojjat Ahmadzadehfar, et al.
Oncotarget|December 22, 2017
Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapyHojjat Ahmadzadehfar, Stephan Schlolaut, Rolf Fimmers, et al.
Clinical Nuclear Medicine|February 28, 2018
[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate CarcinomaAmbreen Khawar, Elisabeth Eppard, Jean Phlippe Sinnes, et al.
Clinical Nuclear Medicine|April 25, 2018
Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate CarcinomaAmbreen Khawar, Elisabeth Eppard, Jean Phlippe Sinnes, et al.
Clinical Nuclear Medicine|April 2, 2019
Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine TumorsAnna Yordanova, Harriet Ahrens, Georg Feldmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 19, 2013
Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor modelFlorian C Gaertner, Tobias Wiedemann, Behrooz H Yousefi, et al.
Plos One|May 30, 2009
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cellsEnken Drecoll, Florian C Gaertner, Matthias Miederer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2013
Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesionsMatthias Eiber, Toshiki Takei, Michael Souvatzoglou, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|May 3, 2013
Whole body assessment by ¹⁸F-FDG PET in a patient with infective endocarditisAtsuro Masuda, Osamu Manabe, Masanao Naya, et al.
Oncotarget|December 29, 2016
Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade gliomaSied Kebir, Zain Khurshid, Florian C Gaertner, et al.
Oncotarget|September 15, 2017
Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancerFlorian C Gaertner, Khalil Halabi, Hojjat Ahmadzadehfar, et al.
Oncotarget|December 22, 2017
Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapyHojjat Ahmadzadehfar, Stephan Schlolaut, Rolf Fimmers, et al.
Clinical Nuclear Medicine|February 28, 2018
[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate CarcinomaAmbreen Khawar, Elisabeth Eppard, Jean Phlippe Sinnes, et al.
Clinical Nuclear Medicine|April 25, 2018
Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate CarcinomaAmbreen Khawar, Elisabeth Eppard, Jean Phlippe Sinnes, et al.
Clinical Nuclear Medicine|April 2, 2019
Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine TumorsAnna Yordanova, Harriet Ahrens, Georg Feldmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 19, 2013
Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor modelFlorian C Gaertner, Tobias Wiedemann, Behrooz H Yousefi, et al.
Plos One|May 30, 2009
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cellsEnken Drecoll, Florian C Gaertner, Matthias Miederer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2013
Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesionsMatthias Eiber, Toshiki Takei, Michael Souvatzoglou, et al.
Pageof 6